SUOMEN PUNAINEN RISTI, VERIPALVELU Patent applications |
Patent application number | Title | Published |
20130230859 | USE OF BLOOD GROUP STATUS - The present invention relates to use of the non-secretor/secretor blood group status of an individual as a criterion for need of | 09-05-2013 |
20130195820 | USE OF BLOOD GROUP STATUS III - The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 08-01-2013 |
20130101560 | USE OF ABO TYPE - The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups. | 04-25-2013 |
20130034901 | Use of a Proteolytic Enzyme for the Modification of the Cell Surface of a Stem Cell - The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme. | 02-07-2013 |
20120315250 | PROBIOTIC BIFIDOBACTERIAL COMPOSITION IN ACCORDANCE WITH SECRETOR BLOOD GROUP STATUS - The present invention relates to a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. The present invention further relates to a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual. | 12-13-2012 |
20120301435 | PROBIOTIC BIFIDOBACTERIAL COMPOSITION IN ACCORDANCE WITH SECRETOR BLOOD GROUP STATUS - The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype. | 11-29-2012 |
20120202701 | AN ANTIBODY-GLYCAN COMPLEX TARGETING THE DISIALYL CORE II AND SIALYL LEWIS X STRUCTURES, AND USES THEREOF INVOLVING ANALYSIS OF STEM CELLS OR CANCER CELLS - Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies. | 08-09-2012 |
20120190058 | METHOD FOR EVALUATING CELL POPULATIONS - The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. | 07-26-2012 |
20120129712 | ANTIBODIES DIRECTED TO TRA ANTIGENS, AND METHODS OF PRODUCTION, SCREENING AND ANALYSIS OF SAID ANTIBODIES, AS WELL AS METHODS OF ANALYSIS OF STEM CELLS AND CANCER CELL - A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex. | 05-24-2012 |
20120115180 | USE OF ANIMAL CELLS FOR SCREENING PROBIOTIC BACTERIA STRAINS - The present invention relates to an in vitro and/or ex vivo method of screening probiotic bacterial strains. The present invention also relates to a method of assessing quality of probiotic culture. In addition, the present invention relates to use of animal cells in screening of a probiotic strain. The present invention also relates to use of animal cells in assessing quality of probiotic culture. | 05-10-2012 |
20120020941 | USE OF BLOOD GROUP STATUS III - Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 01-26-2012 |
20110306128 | CULTURE OF CELLS - The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates. | 12-15-2011 |
20110274646 | Compounds and Combinations - The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer. | 11-10-2011 |
20110217724 | METHOD OF PROTECTING CELLS - Provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system by adding to the graft at least one factor capable of inhibiting the complement. Also provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system using a factor capable of inhibiting the complement. | 09-08-2011 |
20110158951 | USE OF BLOOD GROUP STATUS II - Provided is a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. Further provided is a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype. | 06-30-2011 |
20110158950 | USE OF BLOOD GROUP STATUS I - Provided is a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. Further provided is a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual. | 06-30-2011 |
20110143373 | METHOD OF EVALUATING THE INTEGRITY OF THE PLASMA MEMBRANE OF CELLS BY DETECTING GLYCANS FOUND ONLY INTRACELLULARLY - The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged. | 06-16-2011 |
20110136203 | ENZYMATICAL MODIF ICATION OF CELL GLYCOSYLATION USING SERUM ALBUMIN AND DIVALENT CATIONS - The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. | 06-09-2011 |
20110045497 | NOVEL ACIDIC GLYCAN MARKERS OF HUMAN CELLS - The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules. | 02-24-2011 |
20100292095 | HUMAN MONOCLONAL ANTIBODIES DIRECTED TO SIALYL LEWIS C, SIALYL TN AND N GLYCOLYLNEURAMINIC ACID EPITOPES AND A METHOD OF ANALYSIS OF STEM CELLS COMPRISING SAID EPITOPES - This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients. | 11-18-2010 |
20100120142 | CULTURE OF HUMAN EMBRYONIC CELLS - The invention relates to a method for culturing human embryonic stem cells (hESCs) with a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and a culture medium composition containing a lectin. | 05-13-2010 |
20100068806 | NOVEL METHODS AND REAGENTS DIRECTED TO PRODUCTION OF CELLS - The present invention provides methods and materials to modulate and grow stem cells by contacting stem cells with a binder recognizing terminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders. | 03-18-2010 |
20100055710 | Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof - The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces. | 03-04-2010 |
20100055678 | Method of profiling a cell population - The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAcα3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method. | 03-04-2010 |
20100047827 | NOVEL SPECIFIC CELL BINDERS - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies. | 02-25-2010 |
20100028913 | NOVEL CARBOHYDRATE FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies. | 02-04-2010 |
20090317788 | Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof - The present invention discloses a method of evaluating the status of a stem cell preparation comprising the step of detecting the presence of a glycan structure or a group of glycan structures in said preparation. The detection step can be performed by the use of a lectin specific to a glycan structure of interest. | 12-24-2009 |